The final report from Hilary Cass on UK gender identity services for children and adolescents has some good recommendations, but overall has ended up feeding hostility towards trans people. It implicitly frames trans people as “not real” but having a mental health disorder. The associated NHS decision to rule out puberty blockers for young trans people except when they are on a (yet to be established) clinical trial is a huge setback.
Looking at the positives first, the review highlights the woeful level of service provision. NHS waitlists are over five years, meaning that many young people age out before seeing a clinician. It recommends expanded capacity through a distributed service model, a holistic assessment, and individualised care plans. However, similar recommendations from the 2022 interim report have not been enacted by the NHS.
On the downside, there are multiple problems with the review’s methodology and what evidence and which people have been included and excluded.
The review rejected the vast majority of evidence relating to puberty blockers (medication to delay puberty given to children facing early puberty, and to some young trans kids), and included only two of 102 studies. The argument is that the excluded studies do not include a no-treatment group, and none of them have a “blinded” group (a group which doesn't know whether it is getting placebo or the medication).
But there are strong ethical arguments for why you cannot deny appropriate treatment; and you cannot run a “blinded” group for puberty blockers. Those who are not receiving them will know, because they will undergo puberty. The claim of a low level of evidence is based on excluding the large body of evidence that guides professional organisations around the world which have produced guidelines and standards of care.
As Pang et al 2022 put it when discussing the 2022 Cass review interim report: “The American Academy of Pediatrics, the Endocrine Society, and the World Professional Association for Transgender Health have all endorsed the use of these hormonal treatments in gender-diverse young people, but curiously these consensus based clinical guidelines and position statements receive little or no mention”.
The Australian Professional Association for Trans Health has established local guidelines and the Board commented: “The Cass Review dismisses decades of research and support for the efficacy of puberty blockers and gender affirming hormones in gender-affirming care and effectively recommends that Gender Affirming Care be replaced primarily with psychotherapy and antidepressants, with gender affirming hormones and puberty blockers to be considered only with extreme caution and by a national multidisciplinary team.”
The Cass review’s Assurance Committee and other structures include no trans people, and did not include clinicians implementing the consensus standards of care. However, they did include people who challenge the use of puberty blockers and treat trans people as mentally ill.
There is a large contrast between what is happening in the UK and in Australia. In recent years in Australia, state-funded public hospital Gender Clinics for children and adolescents have been established across the country. They face staffing pressures, but the government response has been much more supportive than in the UK.
The longest established of these clinics, at the Royal Children’s Hospital in Melbourne, set up an ongoing cohort study in 2020 to allow assessment of long term outcomes for their clients. And in 2023, the federal government awarded a large research grant ($5 million over four years) to compare the models of care and their outcomes across all the gender clinics in the country. I personally am excited to be an investigator on that research project.
Overall, the Cass review represents a major blow to providing affirming care to young trans and ender diverse people. As Freddy McConnell put it:
“If the Cass review was held under a black light, we would see the fingerprints of anti-trans ideology. I don’t believe Cass shares this way of thinking, I think she believes in evidence-based healthcare and that trans children exist. However, allowing her review to be so heavily influenced by bias is a critical failure that is hers to own.
"As her work is used, as it will be, to perpetuate a broader hostile environment towards trans people in the UK, the young people she has tried to help will, understandably, feel betrayed.”
• I work in research positions at an Australian university and a Gender Clinic and am a member of the Australian Professional Association for Trans Health Research and Education committees: my views in this article are in a private capacity and not on behalf of those organisations.